Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-ETC-1002] · 1 trial · 1 indication
using mass balance recovery
| Arm | Type | Description |
|---|---|---|
| 1 dose of [14C-ETC-1002] | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| [14C-ETC-1002] | DRUG | - |
Inclusion Criteria: * Healthy Male Volunteers * BMI 10-35 kg/m2 Exclusion Criteria: * Hx of CV, renal, hepatic, chronic respiratory or GI disease * Hx of drug or alcohol abuse * smoking within 12 mos of screening
[14C-ETC-1002] is an investigational radiolabeled form of ETC-1002 being studied in hyperlipidemia. It is used in a Phase 1 clinical trial to investigate the absorption, metabolism and excretion of the drug. The study enrolled 6 healthy male volunteers aged 30 years and older in the United Kingdom.
[14C-ETC-1002] is being developed by Esperion Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker ESPR. The company is conducting a Phase 1 clinical trial of the drug in hyperlipidemia.
[14C-ETC-1002] is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial, which is completed, enrolled 6 participants and was conducted in the United Kingdom.
[14C-ETC-1002] has one completed Phase 1 clinical trial registered as NCT02044627, titled 'Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002'. The study enrolled 6 healthy male volunteers with hyperlipidemia in the United Kingdom.
[14C-ETC-1002] is a radiolabeled version of ETC-1002, used specifically in a clinical study to track the drug's absorption, metabolism and excretion. The radiolabel allows researchers to follow the compound in the body. The Phase 1 trial NCT02044627 was designed to investigate these properties.